Medication Aims to Improve Moderate COVID-19 Symptoms Request More Information Trial Objective This study is to find out if an investigational drug, called dapansutrile, safely and effectively improves symptoms of moderate COVID-19. Researchers also want to know if dapansutrile shortens the time that a patient is sick with COVID-19. To qualify, participants must have tested positive for COVID-19 and have experienced their first symptoms of the virus within five days of becoming part of the study. Half of the participants in this trial will receive the medication and half of the participants will receive a placebo, which looks like the drug but has no medication. The medication or placebo will be taken twice a day for 14 days. Enrollment Active Clinical Trials Currently Recruiting Who Can Participate People who have tested positive for COVID-19 and have experienced their first symptoms of the virus within five days of becoming a participant in the study, who also have a fever and shortness of breath may be eligible for the study. Age: 18+ Gender: Any Gender Estimated Time Commitment Not Specified While taking the medication or placebo, participants will be asked to come into the clinic on days 1, 4, 8 and 15. Participants will be asked to complete two phone calls with researchers on day 29 and day 45. × Payments are intended to compensate the participant for their time and effort during the study. Payments are typically given to the participant at the end of each completed study visit. Reimbursements are intended to compensate the participant for travel-related expenses. They must be approved by the study staff and require you to turn in receipts. Travel reimbursement will vary from study to study. Payment & Reimbursement Payment: Provided Travel Reimbursement: Not Available Trial Contact For more information, contact: Cole Waliczek 303.270.2844 Request More Information Trial Location National Jewish Main Campus, Denver, CO Trial Sponsors Olatec Therapeutics LLC Principal Investigators Michael Wechsler, MD, MMSc + × Michael Wechsler, MD, MMSc Director, The Cohen Family Asthma Institute Professor Department of Medicine Division of Pulmonary, Critical Care & Sleep Medicine View Full Profile Patient Rating 5 out of 5 stars Make an Appoinment Co-Investigators Barry Make, MD + × Barry Make, MD Professor Department of Medicine Division of Pulmonary, Critical Care & Sleep Medicine View Full Profile Make an Appoinment Vamsi Guntur, MD, MSc + × Vamsi Guntur, MD, MSc Associate Professor Division of Pulmonary, Critical Care & Sleep Medicine Department of Medicine View Full Profile Patient Rating 4.7 out of 5 stars Make an Appoinment William Janssen, MD + × William Janssen, MD Section Head, Critical Care Medicine Professor of Medicine Section of Critical Care Medicine Division of Pulmonary, Critical Care & Sleep Medicine Department of Medicine View Full Profile Make an Appoinment Request More Information By completing this form, you agree to learn more about this study and see if you qualify. First Name:* Last Name:* Email Address:* Phone:* I would also like to receive periodic emails with health information, news and clinical research updates from National Jewish Health: YesNo
Trial Objective This study is to find out if an investigational drug, called dapansutrile, safely and effectively improves symptoms of moderate COVID-19. Researchers also want to know if dapansutrile shortens the time that a patient is sick with COVID-19. To qualify, participants must have tested positive for COVID-19 and have experienced their first symptoms of the virus within five days of becoming part of the study. Half of the participants in this trial will receive the medication and half of the participants will receive a placebo, which looks like the drug but has no medication. The medication or placebo will be taken twice a day for 14 days.